Clinical Trials Logo

Neoplasms, Breast clinical trials

View clinical trials related to Neoplasms, Breast.

Filter by:

NCT ID: NCT00462956 Completed - Neoplasms, Breast Clinical Trials

GW572016 In Patients With Advanced Or Metastatic Breast Cancer

Start date: June 30, 2004
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the efficacy and safety of GW572016 in patients with refractory breast cancer and consists of two cohorts of patients. Patients in Cohort A must have ErbB2 overexpressing tumors while patients in Cohort B must have non-ErbB2 overexpressing tumors. Patients eligible for this study must have advanced metastatic breast cancer who have previously received treatment with anthracycline and taxane.

NCT ID: NCT00444535 Completed - Neoplasms, Breast Clinical Trials

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Start date: February 27, 2007
Phase: Phase 2
Study type: Interventional

This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.

NCT ID: NCT00429299 Completed - Neoplasms, Breast Clinical Trials

Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer

CHERLOB
Start date: August 2006
Phase: Phase 2
Study type: Interventional

Evaluate the activity of Trastuzumab, Lapatinib, and a combination of both agents with chemotherapy in the preoperative (neoadjuvant) treatment of early breast cancer.

NCT ID: NCT00422903 Completed - Neoplasms, Breast Clinical Trials

Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer

Start date: April 2007
Phase: Phase 2
Study type: Interventional

Evaluate the percentage of clinical objective responses (cOR) in patients with HER2 negative early breast cancer treated with pre operative (neoadjuvant)lapatinib and letrozole

NCT ID: NCT00388076 Completed - Neoplasms, Breast Clinical Trials

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Start date: April 28, 2006
Phase: Phase 1
Study type: Interventional

Pazopanib will be given with TAXOL in one part, in another part pazopanib will be given with TAXOL and PARAPLATIN, and in a third part pazopanib will be given with TAXOL and lapatinib (patients separated in each part). Toxicity monitoring will enable us to find the largest dose of pazopanib daily that can be safely given in combination with the chemotherapy agents TAXOL and PARAPLATIN, and with lapatinib, as well as what side effects are likely to manifest when these agents are given together and whether the combination of pazopanib with chemotherapy, helps to treat different types of cancer. Another objective is to find out how much pazopanib, TAXOL, PARAPLATIN and lapatinib are in the blood at specific times after the agents are given. Collecting the blood samples requires that the patients remain in the vicinity of the clinic overnight on 2 occasions.

NCT ID: NCT00374322 Completed - Neoplasms, Breast Clinical Trials

Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Start date: August 2006
Phase: Phase 3
Study type: Interventional

This study was designed to evaluate and compare the safety and efficacy of an oral dual tyrosine kinase inhibitor, lapatinib, versus placebo in women with early-stage ErbB2-overexpressing breast cancer who have completed their primary neoadjuvant or adjuvant chemotherapy and have no clinical or radiographic evidence of disease.

NCT ID: NCT00371488 Completed - Neoplasms, Breast Clinical Trials

GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

Start date: April 6, 2006
Phase: Phase 1
Study type: Interventional

This is two-part study (Phase I/Phase II). Part I is designed to find the optimal (best) doses of GW572016 and trastuzumab when given together,Part II is designed to evaluate the tumor response rate (shrinkage or lack of growth) in patients receiving lapatinib and trastuzumab.

NCT ID: NCT00367471 Completed - Neoplasms, Breast Clinical Trials

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

Start date: December 7, 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the optimally-tolerated regimens (OTR) for lapatinib in combination with paclitaxel, carboplatin with and without trastuzumab in patients with metastatic breast cancer.

NCT ID: NCT00359190 Completed - Neoplasms, Breast Clinical Trials

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Start date: June 29, 2004
Phase: Phase 1
Study type: Interventional

This study will examine the inhibition of ErbB1 and ErbB2 phosphorylation and downstream mediators of tumor cell growth and survival tumor tissue in treatment-naive breast cancer patients for three dosing schedules of lapatinib.

NCT ID: NCT00356811 Completed - Neoplasms, Breast Clinical Trials

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Start date: May 2006
Phase: Phase 2
Study type: Interventional

This study investigates the safety and efficacy of oral lapatinib in combination with an approved medication, paclitaxel, for patients with ErbB2 metastatic breast cancer.